3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
11
Neoplasms
7
Cancer Pain
5
Pain, Postoperative
2
Pain, Intractable
2
Lymphoma, Follicular
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Vomiting
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomatitis
1
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Surgery
1
Sleep Wake Disorders
1
Signs and Symptoms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Postoperative Complications
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pathologic Processes
1
Pain Related to Cancer
1
Opioid-Related Disorders
1
Neurologic Manifestations
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
Methadone
×
Clear all
NCT05325164
2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3
Withdrawn